Company Description
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
The company’s lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in phase 2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in phase 1 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction.
The company develops its products through gene editing, cellular regeneration, gene silencing, and gene addition.
The company has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. for discovering novel human genetic targets for the potential development of disease-modifying treatments for cardiovascular diseases.
Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 97 |
| CEO | Faraz Ali |
Contact Details
Address: 171 Oyster Point Boulevard, Suite 500 South San Francisco, California 94080 United States | |
| Phone | 650 825 6990 |
| Website | tenayatherapeutics.com |
Stock Details
| Ticker Symbol | TNYA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 1858848 |
| CUSIP Number | 87990A106 |
| ISIN Number | US87990A1060 |
| Employer ID | 81-3789973 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Faraz Ali M.B.A. | Chief Executive Officer, Interim Principal Financial Officer and Director |
| Dr. Deepak Srivastava M.D. | Scientific Founder, Chairman of Scientific Advisory Board and Director |
| Dr. Whittemore G. Tingley M.D., PH.D. | Chief Medical Officer |
| Dr. Eric N. Olson Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Dr. Bruce R. Conklin M.D. | Scientific Founder |
| Dr. Saptarsi Haldar M.D. | Scientific Founder |
| Dr. Sheng Ding Ph.D. | Scientific Founder |
| Dr. Benoit G. Bruneau Ph.D. | Scientific Founder |
| Tomohiro Higa M.B.A. | Senior Vice President of Finance and Interim Principal Accounting Officer |
| Dr. Kee-Hong Kim Ph.D. | Chief Technology Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 11, 2026 | 10-K | Annual Report |
| Mar 11, 2026 | 8-K | Current Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 26, 2026 | SCHEDULE 13D/A | Filing |
| Feb 25, 2026 | 144 | Filing |
| Feb 25, 2026 | 144 | Filing |
| Feb 20, 2026 | 144 | Filing |
| Feb 20, 2026 | 144 | Filing |
| Feb 17, 2026 | 144 | Filing |
| Feb 17, 2026 | 144 | Filing |